Over a decade into selling Korlym to treat endogenous hypercortisolism, also known as Cushing syndrome, Corcept Therapeutics ...

The phase II DAZALS study evaluating Corcept's dazucorilant in patients with amyotrophic lateral sclerosis fails to meet the primary goal.

Victoria Lucio is a stay-at-home mom of two from Amarillo who has been silently battling with Cushing’s Disease for around ...

Corcept Therapeutics’ selective cortisol modulator failed to slow the progress of amyotrophic lateral sclerosis (ALS) in a ...

The field of molecular and biochemistry diagnostics of adrenal tumors is rapidly evolving, driven by the need to accurately diagnose and manage these complex conditions. Adrenal incidentalomas, which ...

Ourself, a leader in the next generation of skincare, today announced that clinical data evaluating Ourself's patented delivery technology, Tiered-Release Vesiclestm (TRVs), was published ...

Jennifer Sheahan, DVM, DACVO, shares multiple ways nutrition and ophthalmology are linked during her interview with dvm360 prior to her sessions at Fetch Long Beach ...

QIAGEN today announced the launch of Ingenuity Pathway Analysis (IPA) Interpret, a new feature designed to simplify and accelerate the interpretation of complex biological data. Leveraging AI ...

Animals Matter columnist Cathy M. Rosenthal helps pet owners get to the root of Siamese cat's excessive meowing and possible ...

Corcept Therapeutics' dazucorilant fails Phase 2 ALS trial after missing primary endpoint, following October's Cushing's ...

Brooklynn Chandler Wily, 45, was arrested on Tuesday in San Antonio on criminal charges related to an investor fraud scheme ...

Centene Corp. $58.46 1.56 2.74% ...